Geoff Palmer Ⓥ🌱

🚨 Insightful DEA Report: Illicit marijuana flowers average a THC potency of 16%. 🌿💨 This statistic underscores a significant advantage of purchasing from licensed dispensaries—quality and safety. Unlike the unregulated market, dispensaries offer products that are tested, compliant, and consistent in their THC content. This not only ensures a safer consumer experience but also supports the legal cannabis industry committed to high standards. Why risk the unknown? Choose quality, safety, and reliability every time with dispensary-bought cannabis. Let's advocate for more informed consumer choices and support regulations that emphasize these benefits. Stay informed and choose wisely. #CannabisIndustry #ConsumerSafety #DispensaryQuality #THCPotency #RegulatedCannabis

18

6 Comments

The cannabis industry is evolving rapidly, driven by consumer demand for cannabinoids such as CBD and THC. However, this growth has highlighted the need for tighter regulations to ensure product safety, clear labeling, and responsible marketing. Enter the Cannabinoid Safety and Regulation Act (CSRA), a regulatory framework designed to bring order and transparency to the cannabis industry. #hemp #regulations #Cannabinoid #cannabis #laws #federallaw https://lnkd.in/gphu8-jC

31

2 Comments

A new set of criteria for qualifying for a public convenience and advantage waiver was proposed at today’s Cannabis Control Board meeting. The criteria include the following: 1. Distance from Other Retail Dispensaries: The proposed location must be at least: - 1,000 feet from any existing retail dispensary in jurisdictions with a 1,000-foot minimum distance requirement. - 2,000 feet from any existing retail dispensary in jurisdictions with a 2,000-foot minimum distance requirement. 2. Geographic, Structural, or Topographic Barriers: The existence of barriers (such as waterways, major roadways, highways, or significant travel distances) that separate the proposed location from existing dispensaries. 3. Travel Distance: The actual distance between the proposed location and existing dispensaries, as measured by pedestrian or vehicle routes. 4. Unique Factors of the Proposed Location: Factors that may justify the location, such as: - High consumer demand for additional retail dispensaries or microbusinesses. - The presence of illicit or former illicit cannabis dispensaries near both the proposed and existing locations. - Other relevant factors that may support the need for greater access to adult-use cannabis in the area. 5. Notification to Local Authorities: The licensee must send a notification to the local municipality or community board, informing them of their intention to request a waiver from the Board for not meeting the 1,000-foot or 2,000-foot minimum distance requirement. The municipality or community board will have 45 days to respond before the Board considers the application. Mr. Kagia mentioned that the Board would consider more than this information alone when deciding to grant a waiver and that it would be up to their discretion. Chairman Wright raised concerns about the 45-day period, and the Board voted to approve the criteria with an amendment for licensees who have already received municipal support.

11

1 Comment

So, let's break this down: 2018 The Home Office announce that CBD products are subject to the Misuse of Drugs Regs 2001 (MoDR) Jan 2021 Kit Malthouse asks the ACMD to review CBD products with a focus on whether criminals could extract controlled cannabinoids for illicit use. ACMD respond in December, suggesting a controlled cannabinoid intake of 50 micrograms per 12 controlled cannabinoids, with consideration for THCa Because it can turn to D-9. 2022 FSA start mentioning that they were waiting for Home Office updates on THC levels before applications could be processed 2023 The Home Office, after sitting on the ACMD report for nearly two years, state they agree in principle to the ACMD's findings. If the Home Office accepted those findings, the UK would effectively be working by 0.1% THC for consumer products, and not 1mg per container regardless of size. This would open up trade in the UK, but not to the point where UK companies could truly compete with the EU and US's 0.3%. 2024 The Home Office doubles down on MoDR in licensing updates, effectively dismissing the ACMD opinion and throwing the UK back to the bottom of the trade barrel.. What's more, there's new testing requirements, which come with considerations for 12 controlled cannabinoids, 9 of which have no evidence for the potential of abuse, or to be able to induce a psychoactive event. We've been waiting for that, but recommendations for those 12 cannabinoids was from an ACMD opinion in 2016. The chairman of that group was a known employee of GW Pharmaceuticals, which then calls the intention and integrity of relying on MoDR into question. I find myself drawn to Article 7 of EU Reg 178/2002. (Screenshot in comments) Section 1: health protection chosen in Great Britain may be adopted, pending further scientific information for a more comprehensive risk assessment. There has been no health concerns raised with controlled cannabinoids, only criminal concerns. So, the FSA adopted MoDR, but they should have then gathered scientific information and studies to determine a safe level in consumer products, which shouldn't be governed by drug legislation. That's if there was a safety concern that is, otherwise you would assume that MoDR wouldn't have been announced, and the industry would be working by 0.2% THC. But the FSA has never intended to conduct safety studies, only to follow the Home Office's lead, which shows the FSA has ceded control over foods to an agency that has power of drugs. The funny thing is that I have an email from Paul Tossall saying that the FSA own novel foods whilst saying that the Home Office didn't try to pressure the FSA in 2017 to define all cannabinoids as novel foods. Section 2: If trade is important to you, look for the comment with the screenshot of Article 7 The measures shouldn't impact trade, and the measures should be reviewed within a reasonable timeframe...

19

6 Comments

Here, sharing an article I contributed to: "Rescheduling of Cannabis: What the Experts Think" on CBD Oracle. 🚀 This compilation joins thoughts from a dozen industry experts, around what moving cannabis from Schedule I to Schedule III could mean for everyone involved – from users and researchers to businesses and policymakers. I had the chance to share my thoughts alongside a strong group of other experts in the field. We covered a lot of ground, from legal implications to scientific research and economic impacts. It’s a comprehensive look at a topic that’s more relevant than ever. Check it out the summary here: https://lnkd.in/es5E745R Or the full interviews here: https://lnkd.in/euGCHbiQ This discussion isn't going anywhere... no matter who gets elected, cannabis will be front and center of human culture from now on... Certainly so, if there's anything I have to say about it! 😉 Let’s keep the conversation going! 🌿💬

13

5 Comments

Navigating #Amazon's New #DietarySupplements #Policy can be daunting, but Nuherbs' own Lisa Thomas is here to simplify it for us. In her insightful article, Lisa unpacks the recent updates from Amazon that affect anyone in our industry selling dietary supplements. These changes are crucial for ensuring our products are not only compliant with FDA regulations but also meeting Amazon’s stringent new requirements. From increased scrutiny to mandatory third-party testing, the landscape is shifting. Why is this important? Because these changes underscore a collective effort toward greater transparency, safety, and quality—values that resonate deeply with us at Nuherbs and our commitment to you. https://lnkd.in/gxFWRYsS Let's stay informed and proactive together. If you have questions, reach out to us, and let's ensure your operations align seamlessly with these new standards.

31

1 Comment

📅 Mark your calendars for the next NY Cannabis Control Board meeting on June 11th. Which licenses will make the cut this month? Will the discussions be as dynamic as the last session? I'm particularly eager to see if the CCB plans to approve all licenses recommended by the Office. Stay tuned for updates and insights! 🌿 #CannabisIndustry #CCB #CannabisLicensing #RegulatoryUpdates

4

OTC acetaminophen: responsible for 56,000 emergency department visits, 2,600 hospitalizations, and 500 deaths per year (NIH data) OTC alcohol: more than 178,000 deaths every year, played a role in at least 7.1% of emergency department visits (NIH data) OTC tobacco: more than 480,000 deaths every year or about 1 in 5 deaths (CDC data) OTC aspirin: A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo. (NEJM 2018) OTC PPI (acid reflux drugs): Pooled mortality rate higher among PPI users compared with non‐PPI users; In Charlot et al, 2011, mortality increased during 1‐year follow‐up in people taking PPIs (NIH data) OTC NSAIDs: "From the first day of use, all NSAIDs increase the risk of gastrointestinal (GI) bleeding, myocardial infarction, & stroke." (NIH data) CBD: No deaths; Overdose = good night's sleep; Proven properties: anticonvulsant, anti-cancer, anti-anxiety, antidepressant, anti-inflammatory, anti-psychotic, neuroprotectant, analgesic, antioxidant, anti-addiction, cardioprotective, hepatoprotective, reduces chemo-induced nephropathy and neuropathy, stabilizes blood sugars. When does the stigma end?

53

4 Comments

Learn about the dangers posed by unregulated Delta-8 and other intoxicating, hemp-derived, synthetic cannabinoid products which are widely available throughout our our communities. Please watch this short video to better understand the risks these products pose to our children's health and the public's well-being, then contact your Ohio State Representative and State Senator and let them know that we want regulation of these products in Ohio. https://lnkd.in/eZYFJQxn https://lnkd.in/gEs3Gx7i

8

7 Comments

Lesser-Known Cannabis Component CBG Linked To Improved Memory And Reduced Anxiety, First-Ever Human Trial Finds A lesser-known cannabinoid known as CBG has surprised scientists after a first-ever human clinical trial found that it appears to improve memory, while also “significantly” reducing anxiety and stress. The non-intoxicating cannabinoid might not be as well-known as THC and CBD, for example, but as it’s grown in popularity, researchers at Washington State University (WSU) and the University of California at Los Angeles (UCLA) set out to investigate its therapeutic potential amid anecdotal, survey-based reports about its therapeutic potential. The study, published in the journal Scientific Reports this month, found that cannabigerol, or CBG, caused a “significant overall reductions in anxiety as well as reductions in stress” among study participants compared to the placebo. “CBG also enhanced verbal memory relative to placebo,” with “no evidence of subjective drug effects or impairment.” https://lnkd.in/e-qVWKNP?

2

https://lnkd.in/ey2WJ8k8 "If the David Boies case is successful, then we’re told that it’s a very, very short walk across the street to the IRS Tax Court to get all of those taxes back. I mean, that could be many billions of dollars for the overall industry that they wouldn’t have gotten back necessarily if it was just rescheduling.” #Cannabisindustry #CourtCase #Classification #ControlledSubstanceAct

1

“Prescription Cannabis - Smoking vs Vaping” • The landscape of prescription cannabis consumption has evolved, offering users diverse methods to embrace the plant’s benefits based on individual preference and desired effects • Two prevalent methods today are vaping and smoking • Smoking- Cannabis smoking, a traditional consumption method, involves inhaling the smoke from combusting dried cannabis flower • Vaping - Cannabis vaping has become a modern, popular method, offering a controlled and nuanced experience. Unlike smoking, vaping doesn’t involve combustion; specialized devices heat cannabis concentrates or flower to release cannabinoids and terpenes as vapor • Safety- Regardless of smoking or vaping, understanding health impacts is crucial • As cannabis ages, its chemical composition changes. Improper storage conditions can degrade cannabinoids and terpenes, impacting efficacy. Mold or mildew growth becomes a concern, posing health risks. Store cannabis in a cool, dark, airtight environment, regularly checking for signs of aging or contamination https://lnkd.in/ePdwVrGZ

16

3 Comments

The recent shift towards decriminalizing cannabis possession is a monumental step not just for legal reform but for economic and career opportunities within the burgeoning cannabis industry. This change promises to ease the burden on our legal system, save taxpayer money, and reduce unnecessary incarcerations. More significantly, it opens the door to a regulated market that promotes job creation across various sectors of the industry, from cultivation to retail. This provides stable, long-term careers and fosters professional development in a previously shadowed by legal constraints. As we move forward, decriminalization will also play a crucial role in destigmatizing cannabis, enhancing its acceptance across more communities, and boosting economic participation. Let’s embrace this progressive change as an economic growth and social equity catalyst. #CannabisReform #EconomicGrowth #CareerOpportunities #SocialChange Errol FranadaBrian NebelSean CarrDennis O'MalleyMorgan MichelTaylor StinchfieldDylan Wang Christopher D. F. Penny CookConnor JuhlMarine FabreLance WomachBrennan BeauchampArionna Killpatrick Kyle Schierer, SHRM-SCPMFUSEDAlex WelpAdam MeleroMark ShinJady AnkenyIke Watson

33

The Drug Enforcement Administration (DEA) has made an extraordinary decision, aligning with the top federal health agency to shift marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). This momentous step comes after more than fifty years since cannabis was initially listed as a strictly prohibited substance, equated with heroin, devoid of any recognized medical benefits, and carrying a significant potential for abuse. The reclassification of marijuana to Schedule III, as advised by the U.S. Department of Health and Human Services (HHS), carries immense implications for state-legal cannabis businesses. Upon implementation, this move will enable cannabis companies access to federal tax deductions that were previously off-limits to them under the IRS code, section 280E. #reschedule #cannabisindustry #280e #bloommedicinals #wondergrovecannabis #msos #medicalcannabis

22

4 Comments